Merck's Bold Move: Eyes on Springworks in Potential $4 Billion Acquisition

Merck KGaA is in advanced negotiations to acquire U.S.-based Springworks Therapeutics, a move that could rank among the largest pharma deals for Merck. This potential acquisition aims to boost Merck's cancer treatment pipeline amidst a challenging landscape for the German healthcare giant.

Merck KGaA, a prominent player in the global healthcare and technology sectors, is negotiating a significant acquisition deal with Springworks Therapeutics, a U.S. firm specializing in cancer and rare disease treatments.

The talks are reportedly in advanced stages, with a potential deal possibly being signed in the coming weeks. This acquisition could mark one of Merck's largest in recent years, reinforcing its commitment to expanding its cancer treatment portfolio.

The move comes at a time when dealmaking in the U.S. healthcare sector shows signs of revival. Merck's strategic interest in Springworks underscores its focus on bolstering its position in the competitive landscape of cancer therapies.

(With inputs from agencies.)